BioLineRx (BLRX) Operating Income (2011 - 2026)

BioLineRx's Operating Income history runs 14 years deep, the most recent figure standing at -$3.4 million for Q4 2025.

• In Q4 2025, Operating Income rose 23.5% year-over-year to -$3.4 million; the TTM figure through Dec 2025 stood at -$10.3 million (up 49.59% YoY), while the FY2025 annual figure was -$10.3 million, up 49.59% from the prior year.
• Operating Income for Q4 2025 stood at -$3.4 million, down from -$2.2 million in the prior quarter.
• The five-year high for Operating Income was -$2.2 million in Q3 2025, with the low at -$18.6 million in Q4 2023.
• The 5-year median for Operating Income is -$6.1 million (2021), against an average of -$6.7 million.
• The sharpest annual moves came in 2023 and 2024: Operating Income plunged 121.08% in 2023, then soared 76.16% in 2024.
• BioLineRx's Operating Income stood at -$6.6 million in 2021, then declined by 27.28% to -$8.4 million in 2022, then slumped by 121.08% to -$18.6 million in 2023, then jumped by 76.16% to -$4.4 million in 2024, then rose by 23.5% to -$3.4 million in 2025.
• Business Quant data shows BLRX's Operating Income at -$3.4 million in Q4 2025, -$2.2 million in Q3 2025, and -$2.3 million in Q2 2025.